**Supplementary Table 2. Characteristics of matched patients with liver cirrhosis and chronic hepatitis without hepatocellular carcinoma**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Cirrhosis without HCC | Chronic hepatitis without HCC |  |
| Mean ± S.D. | N = 22 | N = 22 | *p*-value | 　 |
| Age, years  | 59.0 | ± | 10.9 | 60.8 | ± | 14.4 | 0.6388 |  |
| Gender, N | 10/12 | 12/10 | 0.5462 |  |
| F/M (%) | (45/55) | (55/45) |  |  |
| Etiology, N | 11/1/0/6/4 | 8/2/0/5/6 | 0.7644 |  |
| HCV/HBV/alcohol/MASLD/others (%) | (50/5/0/27/18) | (36/9/0/23/32) |  |  |
| ALBI score | -2.1 | ± | 0.6 | -2.5 | ± | 0.4 | 0.0050 | \* |
| FIB-4 index | 7.3 | ± | 7.2 | 2.4 | ± | 1.9 | 0.0038 | \* |
| MELD-Na | 9.1 | ± | 3.8 | 7.1 | ± | 1.0 | 0.0180 | \* |
| Total FAs, μg/mL | 2958.9 | ± | 704.3 | 3012.8 | ± | 535.7 | 0.7762 |  |
| SFAs, μg/mL | 997.0 | ± | 245.7 | 951.7 | ± | 171.5 | 0.482 |  |
| Relative amount, % | 33.6 | ± | 1.8 | 31.6 | ± | 1.6 | 0.0003 | \* |
| MUFAs, μg/mL | 782.1 | ± | 189.3 | 712.2 | ± | 128.5 | 0.1588 |  |
| Relative amount, % | 26.5 | ± | 2.0 | 23.8 | ± | 3.3 | 0.0018 | \* |
| n-3 PUFAs, μg/mL | 199.7 | ± | 90.4 | 266.3 | ± | 120.3 | 0.0441 | \* |
| Relative amount, % | 6.8 | ± | 2.3 | 8.8 | ± | 3.3 | 0.0289 | \* |
| n-6 PUFAs, μg/mL | 980.0 | ± | 264.1 | 1082.7 | ± | 244.3 | 0.1877 |  |
| Relative amount, % | 33.0 | ± | 3.6 | 35.8 | ± | 4.2 | 0.022 | \* |
| SMI, cm2/m2 | 35.3 | ± | 9.8 | 40.0 | ± | 5.6 | 0.0571 |  |
| Presence of Sarcopenia, N | 16/6 | 10/12 | 0.0638 |  |
| sarcopenia/non-sarcopenia (%) | (73/27) | (45/55) |  |  |

S.D., standard deviation; HCV, hepatitis C virus; HBV, hepatitis B virus; MASLD, metabolic dysfunction-associated steatotic liver disease; BCLC, Barcelona Clinical Liver Cancer; ALBI, albumin-bilirubin; FIB-4, fibrosis-4 score; MELD, the model of end-stage liver disease; FA, fatty acid; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; CRP, C-reactive protein; SMI, skeletal muscle mass index.

\*: *p*-value < 0.05